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Background. The variation of venom composition with geography is an important aspect of intraspecific variability in the
Vipera genus, although causes of this variability remain unclear. The diversity of snake venom is important both for our
understanding of venomous snake evolution and for the preparation of relevant antivenoms to treat envenomations. A
geographic intraspecific variation in snake venom composition was recently reported for Vipera aspis aspis venom in France.
Since 1992, cases of human envenomation after Vipera aspis aspis bites in south-east France involving unexpected
neurological signs were regularly reported. The presence of genes encoding PLA2 neurotoxins in the Vaa snake genome led us
to investigate any neurological symptom associated with snake bites in other regions of France and in neighboring countries.
In parallel, we used several approaches to characterize the venom PLA2 composition of the snakes captured in the same areas.
Methodology/Principal Findings. We conducted an epidemiological survey of snake bites in various regions of France. In
parallel, we carried out the analysis of the genes and the transcripts encoding venom PLA2s. We used SELDI technology to
study the diversity of PLA2 in various venom samples. Neurological signs (mainly cranial nerve disturbances) were reported
after snake bites in three regions of France: Languedoc-Roussillon, Midi-Pyre ´ne ´es and Provence-Alpes-Co ˆte d’Azur. Genomes
of Vipera aspis snakes from south-east France were shown to contain ammodytoxin isoforms never described in the genome of
Vipera aspis from other French regions. Surprisingly, transcripts encoding venom neurotoxic PLA2s were found in snakes of
Massif Central region. Accordingly, SELDI analysis of PLA2 venom composition confirmed the existence of population of
neurotoxic Vipera aspis snakes in the west part of the Massif Central mountains. Conclusions/Significance. The association
of epidemiological studies to genetic, biochemical and immunochemical analyses of snake venoms allowed a good evaluation
of the potential neurotoxicity of snake bites. A correlation was found between the expression of neurological symptoms in
humans and the intensity of the cross-reaction of venoms with anti-ammodytoxin antibodies, which is correlated with the level
of neurotoxin (vaspin and/or ammodytoxin) expression in the venom. The origin of the two recently identified neurotoxic
snake populations is discussed according to venom PLA2 genome and transcriptome data.
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INTRODUCTION
Snake venoms are complex mixtures of biologically active proteins.
They contain several enzymes and toxins that act in synergy to fulfill
the two mainfunctions of the venom that are subduing and digesting
prey. Diversity of snake venom within species has repeatedly been
described over the last twenty years. The variation of venom
composition with geography is an important aspect of this
intraspecific variability. Several species of medical importance
belonging to Viperidae and Elapidae families produce different clinical
symptoms across the geographical range of their distribution
[1,2,3,4,5]. The causes of this variability remain unclear [6,7]. In
somecasesthevalidityofthedefinitionofthespeciesisnecessaryand
the apparent intraspecies variation is really interspecies variation.
Interspecies hybridization may be a major mechanism of di-
versification of the composition of snake venoms. Whatever the
origin, the diversity of snake venom is important both for our
understanding of venomous snake evolution and for the preparation
of relevant antivenoms to treat envenomations [5,6,8,9].
Three species of venomous snakes are of medical importance in
Europe: Vipera aspis, Vipera berus and Vipera ammodytes (Vam). The
clinical features of Vipera aspis aspis (Vaa)a n dVipera berus berus (Vbb)
envenomations are mostly local, but can be associated with systemic
signs (gastrointestinal and coagulation disorders, low blood pressure)
in cases of severe envenomation [10,11]. Envenomation by Vipera
ammodytes ammodytes (Vamam), a species located in Eastern Europe,
can cause neurological symptoms [12]. Vamam venom contains
neurotoxic presynaptic phospholipases A2 (PLA2), the three isoforms
of single chain ammodytoxin (AtxA, AtxB, AtxC) [13], whereas the
venom of Vipera ammodytes meridionalis (Vammer), another Vam
subspecies of northern Europe, contains vipoxin, an heterodimeric
postsynaptic PLA2 neurotoxin [14,15,16]. A geographic intraspecific
variation in snake venom composition was recently reported for Vaa
venom in France. Since 1992, the Marseille Poison Center has
regularly observed cases of human envenomation after Vaa bites in
south-east France involving unexpected neurological signs [17,18].
In France, neurological symptoms had previously only been
described in cases of envenomation by a subspecies of Vipera aspis,
Vipera aspis zinnikeri (Vaz) located mainly in the south-west of France
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icity is due to a postsynaptic neurotoxin, PLA2-I, homologous to
vipoxin [20].
The viper responsible for one of these ‘‘neurotoxic’’ envenoma-
tions was classified as Vaa on the basis of its morphology [17]. The
venom gland mRNA of this neurotoxic Vaa snake was sequenced
and led to the identification of two neurotoxins, AtxB, an isoform
of ammodytoxin previously described only in the venom of Vamam,
and vaspin, a neurotoxin similar to PLA2-I and vipoxin [21],
composed of two subunits, an acidic one called vaspin A (vasA)
and a basic one, called vaspin B (vasB). Among the genes encoding
the venom PLA2s of the same neurotoxic snake were genes
encoding ammodytin I1 (AmI1), ammodytin I2 (AmI2), vaspin
and the three isoforms of Atx, as well as a retrotransposon reported
to be a phylogenetic marker of the genome of Vipera ammodytes
species [22,23]; a true Vaa genome only contains genes encoding
AmI1, AmI2 and vaspin from this list. These observations indicate
that there is a previously undescribed population of Vaa snakes in
the south-east of France. This led us to investigate any
neurological symptoms associated with snake bites in other regions
of France and in neighboring Switzerland and Italy. We also
conducted a biochemical and an immunological study of Vipera
snake venoms in the same regions to evaluate the potential
neurotoxicity of the venom samples. In parallel, we analyzed the
venom PLA2 composition of the genome and of the transcriptome
of some snakes. The results allow a better definition of V. aspis sp.
venom neurotoxicity. Analysis of the cross-reactivity of the venoms
with anti-ammodytoxin antibodies indicated that only a restricted
population of Vaz snakes found only in areas of contact with other
snake species is able to cause neurological symptoms. We also
describe a geographical variation in the composition of Vaa venom
in the southwestern part of ‘‘Puy-de-Do ˆme’’ department: it is
indistinguishable from a pure Vaz venom.
MATERIALS AND METHODS
Material
Pooled Vaa and pooled Vaz venoms were purchased from Latoxan
(Valence, France).
Methods
Epidemiological and clinical analysis of snake bites and
ecological analysis of Vipera snakes This study is not
a clinical trial. The patients were treated as usual like every
envenomed victims in France, explaining why no special approval
was necessary. The sole difference was the clinical feature with
a new observed neurotoxicity, but there were no treatment
protocol modifications in the medical management. Analytical
assays were performed in blood samples collected for the classical
exploration of bitten patients in order to evaluate the clinical
gradation. Snake bites were analyzed retrospectively in 7 regions
of France (Aquitaine, Auvergne, Midi-Pyre ´ne ´es, Languedoc-
Roussillon, Pays de Loire, Provence-Alpes-Co ˆte d’Azur, Rhone-
Alpes) from 1990 to 2002 (Figure 1). Unusual cases of neurotoxic
envenomation reported by the Marseille Poison Centre from 2003
to 2005 were also included. Patient data (age, sex, time of bite,
Figure 1. Regions of France involved in the medical and herpetological survey of Vipera aspis envenomation. The regions and departments
(indicated by numbers) where the medical and herpetological surveys were conducted are shown in light grey.
doi:10.1371/journal.pone.0001194.g001
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of envenomation of each patient was determined according to the
classification established by [24]. Grade 1 envenomations (mild
envenomations) were identified by the presence of local signs and
absence of systemic symptoms; grade 2 (moderate envenomations)
by regional oedema and moderate systemic symptoms; grade 3
(severe envenomation) by extensive oedema and severe systemic
symptoms. Epidemiological data from 110 patients that presented
a minor, moderate or severe envenomation were collated using
Excel and Epi-Info software. We then excluded from the study
cases of envenomation for which no indication of department was
mentioned.
Authorization for capture and transportation of Vipera aspis and
Vipera berus snakes in France were obtained from the prefectures of
the following French administrative departments: ‘‘Alpes de Haute-
Provence’’ (code no. 04), ‘‘Alpes-Maritimes’’ (code no. 06), ‘‘Puy-de-
Do ˆme’’ (code no. 63), ‘‘Arie `ge’’ (code no. 09), ‘‘Haute-Pyre ´ne ´es’’
(code no. 65), ‘‘Gironde’’ (code no. 33), ‘‘He ´rault’’ (code no. 34),
‘‘Loire-Atlantique’’ (code no. 44), ‘‘Haute-Savoie’’ (code no. 74), and
‘‘Seine-et-Marne’’ (code no. 77) (see Figure 1). For Vipera ursinii (Vu)
and Vam capture, transportation authorizations were obtained from
the Ministry of Ecology and Sustainable Development of France.
Vipera ammodytes montandoni (Vammon) snakes were captured at Strazha
(Bulgaria), Vipera aspis francisciredi (Vaf) in Piemont (Italy), Vipera aspis
huguy (Vah) in Calabria (Italy) and Vipera latastei latastei (Vll)i nt h e
region of Burgos (Spain). Seventy-two snakes were collected. The
scientists in charge of snake captured in the various regions filled in
a questionnaire. The data collected, indicating the sex, age and
biotope (precise geographical localization, altitude) for each animal
captured in France, are listed in Supplementary Table S1. They
were identified by use of classical keys (including the numbers of
ventral and sub ocular plates, scales between the labial plates and the
eyes). When the dorsal pattern was clearly distinguishable from that
of other Vipera aspis snakes from the same department, the subspecies
was not indicated and replaced by a question mark. Snakes were
milked, then killed and their organs were kept at 280uCu n t i l
analysis. Additional Va snake venoms were collected in the south-
west of France and Vaf snake venoms were collected in three regions
of Italy: Calabria, Liguria and Tuscany.
PLA2 transcript preparation from venomous gland and
genomic DNA extraction Total RNA was extracted as
described previously [25]. RT-PCR, ligation, molecular cloning,
plasmid DNA extraction and sequencing reactions were
performed as previously described [26]. Total genomic DNA
from tissue samples (liver, muscles, kidney or skin) was extracted as
described by [27].
PLA2 gene screening by PCR PCR was performed using
genomic DNA and/or cDNA extracts. The primers specific to
each PLA2 species were designed to confirm whether a given type
of transcript was present in the venom gland of a specimen, or
whether the corresponding gene was present in the genome of the
specimen. AmI1 and AmI2 were amplified with 59gacggggatattt-
ggtataatgtcc39/39gcaatgagaggatgggtagttc59 and 59gggaacctttacca-
gttcggg39/39gcaatgagaggatgggtagttc59, respectively. The acidic
subunits of vaspin and vipoxin were amplified with 59caaaagacg-
gggaaagaagc39/39tcctccgtgcaatgagagattg59 primers. The basic
ones were amplified with 59gcctgctcgaattcgggatg39/39gtctgcctgcat-
ctagagga59. The Bov-B line retroposon was amplified with
59gagtggatgcacagtcgttg39/39ctccttcttgcacaaaaagtg59 primers.
Ammodytin L (AmL) was amplified using the following set of
primers: 59 gtgatcgaatttgggaag atgatcca39/39cccttgcatttaaacctcagg-
tacac59. The primers for AtxB PLA2 were 59gcctgctcgaattcggg-
atg39/39ctccttcttgcacaaaaagtg59 whereas, 59ctgctcgaattcgggatg39/
39 gtcygggtaattcctatata59 were specific for AtxA or C. The PCR
products obtained with primers specific to Atx A/C were purified
and incubated with restriction enzyme HpaII for 4 hours at 37uC
to test for the presence of AtxA. AtxA contains an extra HpaII site
to AtxC, yielding four cDNA fragments (63, 51, 129 and 201 bp)
instead of three (63, 180 and 201 bp).
Determination of protein concentration the protein
concentration of venom samples was determined using the
Coomassie plus method (Pierce, Rockford, Il, USA).
Fractionation of pooled Vaa and pooled Vaz snake
venoms The fractionation of pooled Vaa and pooled Vaz
venoms was performed on a column containing Sephadex G100
superfine and using ammonium formiate 1M, pH 3.5 as running
buffer. Fractions of 450 ml were collected at a flow rate of 2.6 ml
per hour. The protein concentration of each fraction was
measured on a spectrophotometer at the wavelength of 280 nm.
Fractions corresponding to the same peak were pooled and tested
for their PLA2 activity by fluorimetry [28].
Microsequencing Venoms 406 and 508 were subjected to
PAGE (20% SDS-polyacrylamide gel) in reducing conditions. For
venom 406, the gel was rinced three times with water and stained
overnight with Amidoblack. A piece of gel containing Atx PLA2 was
cut out and digested with 2 mg/ml of endoproteinase Lys-C
(Boehringer Mannheim GmBH, Mannheim, Germany) for 18 h at
35uC. The digested material was injected onto a DEAE column
linked to a C-18 reversed-phase HPLC column and eluted with a 2–
70% acetonitrile gradient in 0.1% trifluoroacetic acid. The
molecular weight of eluted pepides was determined by surface
enhanced laser desorption ionization-time of flight-mass
spectrometry (SELDI-TOF-MS) on a Au proteinChip and the
peptide corresponding to the C-terminal part of Atx was sequenced
on a protein sequencer (494; Applied Biosystems, Foster City, CA).
For venom 508, after the end of the electrophoresis, the gel was
transferred onto PVDF overnight at a constant voltage of 15 V. The
PVDF membrane was then stained with Amidoblack and the band
containing low molecular weight PLA2s wasexcised and subjected to
Edman degradation on an Applied Biosystems 494 sequencer.
Analysis of snake venom PLA2 contents by SELDI-TOF-
MS Venoms were diluted to 1.25 mg/ml in distilled water and
spotted onto a variety of chemical surfaces: reverse phase H4 or
H50 (hydrophobic surface: C-16 or C-4 (long chain aliphatic),
weak cation exchanger (WCX2: carboxylate) or strong anion
exchanger (SAX2: quaternary ammonium). Best and similar
profiles were obtained with WCX2 and H4. H4 chips were
activated with 10% acetonitrile and air dried prior to sample
incubation. Venom samples (2.5 mg, final volume: 2 ml) were
spotted, allowed to dry and spots were washed four times with 5 ml
of distilled water. The samples were then air dried. WCX2 chips
were equilibrated twice for 10 min with 150 ml of 100 mM sodium
acetate pH 3.8, using a bioprocessor. Venom samples (2.5 mg)
were diluted in 100 ml of 100 mM sodium acetate pH 3.8
containing 0.1% Triton and incubated on the chips for 30 min
at room temperature under shaking. Then, the chips were washed:
first for 5 min with 100 ml of 100 mM sodium acetate pH 3.8
containing 0.1% Triton, second, twice with 100 ml of 150 mlo f
100 mM sodium acetate pH 3.8 and finally twice with double-
distilled H2O. The samples were then air dried. Then, 0.5 mlo f
sinapinic acid (Ciphergen) saturated in 0.5 ml of 50% acetonitrile–
0.5% trifluoroacetic acid was applied twice on each spot (WCX2
or H4 ProteinChips) and the spots were air dried. Molecules
retained on the surfaces were visualized by reading the spots of
each array in a SELDI-TOF-MS reader (PBSII; Ciphergen).
Spectra were generated with 175 shots averaged at 210 laser
intensity with a detector sensitivity of 7 and an accelerating voltage
of 20 kV in positive mode with automatic data collection software
Aspis Venom Neurotoxicity
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one spot of each array by using ubiquitin (8564.8 Da), cytochrome
C (12230.9 Da) and beta-lactoglobulin A (18363.3 Da).
Raw spectra were processed and analysed with the Ciphergen
Express data manager software version 3.0 (CE; Ciphergen
Biosystems). Spectra were externally calibrated with ubiquitin
(bovine) (8564.8+1H), cytochrome C (bovine) (12230.9+1H), and
beta-lactoglobulin A (bovine) (18363.3+1H). The baseline was
established using default parameters and spectral intensities were
normalized by total ion current (TIC). Consistent peak sets of
similar mass across the spectra were generated with Ciphergen
Express Cluster Wizard. This Wizard operates in three passes
across the spectra. The first pass performs peak detection at high
signal-to-noise ratio (s/n) to pick out well-defined peaks as starting
points for forming clusters. A second pass selects lower s/n ratio
peaks, within a mass window defined around the first pass peaks.
The algorithm completes the clusters in a third pass by creating
artificial peaks where none were detected in the first two passes, at
the exact centre of clusters. In this analysis, the first pass was
performed with an s/n threshold of 5, and the second pass with an
s/n threshold of 2, in a 0.2% width mass window. Estimated peaks
were added to complete clusters. Clusters were assembled between
13000 and 14000 Da, the expected size of venom toxins. The
cluster lists contained normalized peak intensity values for each
sample within a group and P-values were calculated between the
medians of the peak intensities to detect significant differences in
abundance for particular proteins.
Preparation of anti-ammodytoxin antibodies Rabbit
polyclonal antibodies against AtxA (Latoxan, Rosans, France)
were prepared as described by [29].
Determination of venom immunological crossreactions by
ELISA We determined by western blot the cross-reactivity of anti-
AtxA antibodies (data not shown). They react with vasB and Atx but
don’t bind AmI1 or AmI2. Microtitration plates (Nunc, Roskilde,
Denmark) were coated by incubation overnight at 4uCo r1h ra t
37uCw i t h1 0 0ml of venom solutions (5 mg/ml) diluted in carbonate
buffer (0.01M, pH 9.5). The plates were washed and incubated for
1h ra t3 7 uCw i t h1 0 0ml of various dilutions of rabbit polyclonal
anti-AtxA antibodies in PBS containing 3% BSA (PBS-BSA), then
washed again. Peroxidase-labeled anti-rabbit IgG (100 ml of 1/1000
dilution in PBS-BSA) (Cappel/ICN Biomedicals, Aurora, Ohio,
USA) were added to the wells and the plates were incubated for 1 hr
at 37uC. After washing,substrate medium (100 mlo f1 0m Ms o d i u m
phosphate, pH 7.3, containing 2 mg/ml of OPD and 0.06% of
perhydrol) was added to each well and the plates were incubated for
7 mininthe darkatroom temperature.The reactionwasstoppedby
adding 50 ml of 0.5% sodium sulfite in 2N sulfuric acid to each well.
Absorbance was measured at 490 nm using a microtitration plate
reader (MR5000, Dynatech, France). Optical densities measured at
dilutions of anti-AtxA IgG of 1/16,000 were used for cross-reactivity
gradation: level 0: OD#0.1, level 1: 0.1,OD#0.2; level 2:
0.2,OD#0.3; level 3: 0.3,OD#0.4; level 4: OD.0.4.
RESULTS
Epidemiological study of envenomations in France:
detailed symptomatology of neurotoxic
envenomations according to geographical region
A hundred and ten cases of envenomation were reported between
1990 and 2005 in various regions of France (Aquitaine, Auvergne,
Figure 2. Annual distribution of envenomation cases in France.
doi:10.1371/journal.pone.0001194.g002
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Alpes-Co ˆte d’Azur, Rhone-Alpes). Thirteen cases of envenomation
for which no indication of department was mentioned were then
excluded from the study and ninety-seven cases are reported in
Supplementary Table S2. Envenomation cases were recorded
from March to October (Figure 2A). They were distributed evenly
from May to August in Languedoc-Roussillon (Figure 2B) and
from March to October in Provence-Alpes-Co ˆte d’Azur (PACA)
(Figure 2C) whereas in Auvergne, peaks of envenomation were
observed in May, July and August (Figure 2D). The age
distribution was from 3 to 91 years. The severity of envenomation
of each patient was determined according to the classification
established by [24]. Fifteen cases of grade 1, 58 of grade 2 and 24
of grade 3 were reported. Neurological symptoms were only
observed in grades 2 and 3 and constituted 17% of all moderate
and severe envenomation cases. They were reported from April to
October in four departments, ‘‘Alpes de Haute-Provence’’ (code
no. 04), ‘‘Alpes-Maritimes’’ (code no. 06), ‘‘Aveyron’’ (code no. 12)
and ‘‘He ´rault’’ (code no. 34) (Supplementary Table S2). Figure 3
shows the prevalence of neurological symptoms in grade 2 and 3
envenomations for each department. The neurological signs are
detailed in Table 1. They were mainly cranial nerve disturbances
(ptosis, opthalmoplegia, paresthesia, diploplia and dysphagia).
Ptosis was observed in 100% of the cases. Opthalmoplegia,
drowsiness and dysphagia were recorded in all four departments.
The most varied clinical symptoms were observed in ‘‘Alpes-
Maritimes’’ and ‘‘Aveyron’’ with 9 different neurological signs
(Table 1). We also analyzed the kinetics of appearance of each
symptom. Drowsiness and diploplia were the most precocious
symptoms, with mean appearance times of 5.8362.63 hrs,
4.7562.96 hrs after the envenomation, respectively. Ptosis and
ophtalmoplegia were delayed, occurring after 9.0365.6 hrs and
1066.12 hrs.
Venom PLA2 screening at the genome and
transcriptome level
To correlate the neurological signs observed with the venom
composition, snakes were captured in the geographical regions in
which the epidemiological analyses were conducted. Neurotoxins
previously identified in the venoms of ‘‘neurotoxic’’ French vipers
were phospholipases A2 or their homologs of 13 to 14 kDa. At
least one snake of each region was sacrificed. cDNAs and genes
encoding venom PLA2s were amplified from the venomous glands
of Vipera snakes and probes specific of european viper venom
PLA2s (AmI1, AmI2, vasA, vasB, AtxA/C and AtxB, AmL) were
used for PLA2 profiling.
With regard to the French snake population, four classes can be
identified based on their PLA2 genome composition (Table 2). The
first class is characterized by the presence of genes encoding AmI1
and AmI2 and is only composed of Vaatra snake 651 and Vaa snake
564. Interestingly, this latter snake belongs to an isolated
population of Vaa snake whose biotope is composed of garrigues
and unlike other ‘‘classical’’ Vaa snakes has lost vaspin encoding
genes. The second class, characterized by genes encoding AmI1,
AmI2, vasA and vasB, is composed of Vaa snakes 303 (Loire-
Atlantique), 452, 601, 502 (Puy-de-Do ˆme) and V. ursinii (Vu) snake
620 (Vaucluse). Although they differ in their genome composition,
Figure 3. Distribution of classical and neurotoxic cases of envenomation in various regions of France. Pie charts show the relative numbers of
classical (white) and neurotoxic (black) grade 2 and 3 envenomations. The total number of cases reported in each department is presented as grey
levels, as indicated in the right bottom end corner of the figure.
doi:10.1371/journal.pone.0001194.g003
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and AmI2 in their venoms. The third class is composed of Vaz
snakes 613 (Gironde) and 508 (Hautes-Pyre ´ne ´es) and Vaa 456
(Puy-de-Do ˆme) and possesses genes encoding AmI1 and vaspin.
All the snakes of this class present the same transcriptome profile
for which all the venom PLA2 genes of the genome are expressed.
The fourth class is composed of Vipera aspis snakes 406, 513, 514
(Alpes-de-Haute-Provence) and 603 (Alpes-Maritimes) and pos-
sesses genes encoding AmI1, AmI2, vasA, vasB, AtxA, AtxB and
AtxC as well as the Bov-B line retroposon. Interestingly, their
transcriptome profiles differ at the level of vaspin and ammody-
toxin isoforms expression, viper 603 being the only one that
expressed all neurotoxins genes. This viper was captured after
having bitten a human, who thereafter suffered from ptosis,
ophtalmoplegia, agueusia, paresthesia and muscle weakness
[17,18]. Snake 459 is the only Vaz specimen, which expressed
AmI2 in its venom at the difference of Vaz 613 and 508 snakes that
did not possess AmI2 gene in their genome (Table 2).
We also analyzed the PLA2 genome composition of European
snakes. The genome of Vaf snake captured in Piemont is similar to
that of Vaa whereas that of Vah from Italy contains Atx and AmL
but not vaspin, as does that of Vammon of Bulgaria. Vipera latastei
latastei contains only AmI1 and AmI2 as Vaatra 651 and Vaa 564.
In addition to the complexity of the transcriptome profiles, the
sequencing of transcripts encoding PLA2 genes in Vaa and Vaz
snake venom glands has shown that three isoforms of AmI1 and
two of AmI2 are expressed in the venom of these snakes: the
molecular weight of AmI1 isoforms ranges between 13676 and
13694 Da and that of AmI2 isoforms between 13526 and 13553
Da [30]. Two isoforms of vasA were identified with molecular
weights of 13655 and 13665 Da whereas only one isoform of vasB
was characterized (13841 Da) [30]. All these molecular weights are
indicated assuming that the 14 cysteine residues are engaged in
disulphide bonds.
PLA2 proteome of snake venoms from various
French regions using SELDI-TOF-MS proteinchip
SELDI-TOF-MS ProteinChip technology was used to capture and
analyze proteins of 13 to 14 kDa from crude venom samples.
Several ProteinChips were tested to identify the chemical
interaction able to bind proteins of the expected molecular
weights. Hydrophobic (H4, H50) and hydrophilic (SAX2 and
WCX2) arrays were used to differentiate venom samples from Vaa
(French department ‘‘Loire-Atlantique’’) and Vaz (French de-
partment ‘‘Hautes-Pyre ´ne ´es’’) snakes (4 individual snakes for each
subspecies). Best and similar profiles were obtained using cation-
exchange (WCX2) and H4 (hydrophobic) chromatography
surfaces. Vaa venoms gave 3 peaks at molecular weights between
13500 and 13900 Da, and Vaz venom gave 3 major peaks between
13650 and 14060 Da (Figure 4). According to the the PLA2
transcriptome data of venom of this two subspecies, we would
expect to detect by SELDI, in this range of molecular weights,
AmI1 and AmI2 in Vaa venoms and AmI1, vasA and vasB in Vaz
venoms. To verify whether PLA2s were indeed immobilized on the
SELDI chips, we first resolved pooled Vaa and pooled Vaz venoms
by gel filtration on a Sephadex G75 column (Figure 5A and 5B).
The main fractions presenting PLA2 activity (13 kDa for Vaa and
30 kDa for Vaz venom) were isolated. Proteins contained in these
two fractions were separated by SDS-PAGE (not shown) and
transferred onto PVDF, and stained with Amidoblack. N-terminal
sequences were determined by Edman degradation. Three
sequences were identified in the 13 kDa Vaa PLA2 fraction:
HLSQF (AmI1, 13673 Da, gi:33187128), NLYQF (AmI2, 13553
Table 1. Clinical cases of neurotoxic envenomations
..................................................................................................................................................
French departement Alpes-de-Haute-Provence (04) Alpes-Maritimes (06) Aveyron (12) He ´rault (34) Total
Case number 3 7 3 1 14
M/F 2/1 5/2 2/1 Not mentionned 9/4
Age in years (mini/maxi) 48/88 32/68 4/62 5 4/88
Years 1995 to 1999 1992 to 2005 1998 to 2004 2001 1992 to 2005
Grade 1/2/3 number 0/2/1 0/6/1 0/3/0 0/1/0 0/12/2
Local signs
Local swelling 1 3 2 1 7
Extensive swelling 2 4 1 0 7
Neurological signs
Ptosis 3 7 3 1 14 (100%)
Ophtalmoplegia 2 5 2 1 10 (71%)
Drowsiness 1 4 2 1 9 (64%)
Dysphagia 2 3 1 1 7 (50%)
Dysphonia 0 4 1 1 6 (43%)
Vision troubles * 1 3 1 0 5 (36%)
Paresthesia 0 3 1 0 4 (29%)
Muscle weakness 0 1 1 0 4 (14%)
Lip paralysis 0 2 2 0 4 (28%)
Agueusia 0 1 0 0 1 (7%)
Other systemic symptoms 3 7 3 0 13 (93%)
Antivenom treatment 3 4 2 1 10 (71%)
*accomodation trouble, diplopia
doi:10.1371/journal.pone.0001194.t001
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PLoS ONE | www.plosone.org 6 November 2007 | Issue 11 | e1194Da, gi:33187122) and RDRPM (no hit found by Blast searches).
Two sequences were identified in the 30 kDa Vaz PLA2 fraction:
NLFQFGDMILQK (vasA, 13655 Da, gi:33187114) and
NLFQFAKMINGK (vasB, 13841 Da, gi:33187118). The profile
of these fractions was also analyzed by SELDI (Figure 6A). The
Vaa 13 kDa PLA2 fraction profile gave three peaks, the molecular
weight of the two first peaks (13554 Da and 13673 Da) matching
those of AmI2 and AmI1 respectively; the profile of the Vaz 30
PLA2 kDa fraction (vaspin) contained two main peaks, the first
(13652 Da) consistent with the molecular weight of vasA and the
second (13840 Da) with the molecular weight of vasB. We also
studied the PLA2s of individual Vaz venoms to test for the presence
of AmI1. Venom 508 was separated by SDS-PAGE (20%
acrylamide gel; Figure 6B) and transferred onto a PVDF
membrane. The lowest of the two bands migrating at 14 kDa
was sequenced: a mixture of 2 N-terminal sequences was obtained
corresponding to AmI1 (main sequence, HLSQFGDMIN) and
vasA (NLFQFG) (Figure 6B).
The PLA2 profiles of isolated Vaa and Vaz PLA2 fractions
matched those of the complete venom samples; this confirms that
PLA2s are effectively bound onto the ProteinChip surface. The
first peak of Vaz venoms probably contains a mixture of vasA and
AmI1 PLA2. Indeed, a pure vasA peak, as found in the Vaz
30 kDa PLA2 fraction, was thin (Figure 6A) whereas the peaks
detected in Vaz venoms were thicker (Figure 4).
Next, we analyzed several individual venoms from snakes from
French departments and neighboring countries (Figures 7–11).
Venoms were grouped according to their geographical localization
and/or their subspecies. Vaa-type venoms from the Loire-
Atlantique (code no. 44) and Seine-et-Marne (code no. 77) were
characterized by the presence of two main peaks consistent with
the molecular weights of AmI2 and AmI1 (Figure 7). The relative
abundance of these two proteins differed between the venoms of
this group. Venoms collected in the Puy-de-Do ˆme were classified
into two groups (Figure 8): the PLA2 profiles of 451, 456, 521, 552,
553, 554 and 560 were similar to those of Vaz venoms, whereas the
other profiles were heterogeneous. Venoms from the south-west of
France (Haute-Pyre ´ne ´e, Haute-Garonne, He ´rault) have diverse
PLA2 profiles (Figure 9). Vaz venom 459 presents an additional
peak of AmI2 not found in Vaz venoms from the Hautes-Pyre ´ne ´es.
The PLA2 SELDI profiles of Va venoms from He ´rault were
complex and heterogeneous: AmI2 was found in venoms 504 and
505 but not in venoms 506 and 509. Venom SELDI profiles from
the south-east of France were heterogenous (Figure 10). Their
complexity is in agreement with transcriptome data, which
indicate the presence of AmI1, AmI2, vasA, vasB, AtxA, AtxB,
and AtxC transcripts in the venom glands of some of the snakes
captured in this region [30]. The SELDI profiles suggest that
AmI2 is not present in venom 800. Interestingly, an additional
peak of molecular weight 13751 to 13759 Da was identified in
venoms 406, 458 and 514. SELDI experiments indicate that the
molecular weight of AtxB is 13765 Da and AtxC has a molecular
weight of 13724 Da (Figure 10). The molecular weights of AtxA
and AtxB predicted from their sequences differ only by two Da,
and therefore C-terminal sequencing is required to differentiate
between these two isoforms. Venom 406 was separated by SDS-
PAGE on a homogeneous 20% acrylamide gel (Figure 6B). The
band corresponding to Atx (N-terminal sequence determined by
Edman degradation after transfer onto PVDF membrane: SLLEF,
Figure 6B) was cut out of the gel and digested with LysC. The
peptides were separated by HPLC and the peptide corresponding
to the C-terminal peptide was sequenced (TYNHI) and shown to
Table 2. Genome and transcriptome analysis of snake venom PLA2 ..................................................................................................................................................
Label
number
Administrative French
department or country Viper Genome composition Venomous gland composition (cDNA)
AmI1 AmI2 vasA vasB AtxA AtxB AtxC AmL ART AmI1 AmI2 vasA vasB AtxA AtxB AtxC AmL
406 Alpes-de-Haute-Provence (04) Vaa yes yes yes yes yes yes yes no yes yes yes no no yes yes yes nd
513 Alpes-de-Haute-Provence (04) Va? yes yes yes yes yes yes yes no yes yes yes nd nd nd nd nd nd
514 Alpes-de-Haute-Provence (04) Va? yes yes yes yes yes yes yes no nd yes yes no no no yes no nd
603 Alpes-Maritimes (06) Vaa yes yes yes yes yes yes yes no yes yes yes yes yes yes yes yes nd
459 Haute-Garonne (31) Vaz nd nd nd nd nd nd nd nd nd yes yes yes yes no no no nd
564 He ´rault (34) Vaa yes yes no no no no no no no nd nd nd nd nd nd nd nd
613 Gironde (33) Vaz yes no yes yes no no no no no yes no yes yes no no no nd
303 Loire-Atlantique (44) Vaa yes yes yes yes no no no no no yes yes no no no no no nd
452 Puy-de-Do ˆme (63) Vaa yes yes yes yes no no no no no yes yes no no no no no nd
502 Puy-de-Do ˆme (63) Vaa yes yes yes yes no no no no no yes yes no no no no no nd
601 Puy-de-Do ˆme (63) Vaa yes yes yes yes no no no no no yes yes no no no no no nd
456 Puy-de-Do ˆme (63) Vaa yes no yes yes no no no no no yes no yes yes no no no nd
508 Hautes-Pyre ´ne ´es (65) Vaz yes no yes yes no no no no no yes no yes yes no no no nd
651 Haute-Savoie (74) Vaatra yes yes no no no no no no no yes yes no no no no no nd
620 Vaucluse (84) Vu yes yes yes yes no no no no no yes yes no no no no no nd
605 Italy Vaf yes yes yes yes no no no no no nd nd nd nd nd nd nd nd
604 Italy Vah yes yes no no nd yes nd yes yes nd nd nd nd nd nd nd nd
608 Spain Vll yes yes no no no no no no no nd nd nd nd nd nd nd nd
709 Bulgary Vammon yes yes no no nd yes nd yes yes yes yes no no no no no yes
Venom PLA2 encoding genes were amplified by PCR using specific probes from liver DNA (genomics) and venomous gland cDNA (transcriptome) as described in the
Material and Methods section. ART: Bov-b line retroposon. nd: not determined.
doi:10.1371/journal.pone.0001194.t002
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PLoS ONE | www.plosone.org 7 November 2007 | Issue 11 | e1194correspond to AtxB (Figure 5D). This result is consistent with
transcriptome data, which indicated that few AtxA transcripts are
present in the venom glands of snake 406 [30]. SELDI profiles of
Haute-Savoie Vaatra venoms are very similar to those of Vaa
venoms from Loire-Atlantique (Figure 11). AmI2 appears to be
absent from the venoms of Vaf (Figure 11).
The spectra obtained were grouped into geographical clusters
(cluster A: Loire-Atlantique, cluster B: Puy-de-Do ˆme; cluster C:
Hautes-Pyre ´ne ´es; cluster D: He ´rault; cluster E: Haute-Garonne;
cluster F: Alpes-Maritimes and Alpes-de-Haute-Provence; cluster
G: Seine-et-Marne; cluster H: Vaf from Italy) and analyzed with
CiphergenExpress software to study the relationships between the
profiles. A list of 4 peaks with p-values,0.05 were selected, which
helped discriminating between the various venom samples: 13530
Da (AmI2), 13658 Da (AmI1 or vasA), 13753 Da (AtxA or B) and
13846 Da (vasB). A heat map was generated to see how well
groups could be separated in a non-supervised way, based on the
data set provided: it gave an interesting classification of the venoms
(Figure 12). According to the dendrogram obtained, the venoms
are separated into two major groups. The first group is
distinguished by the down-regulation of the expression of AmI2
(13530 Da) and the over-expression of vasB (13854 Da). The
second group is mainly characterized by the down-regulation of
the expression of vasB. All venoms of Hautes-Pyre ´ne ´es and
He ´rault are clustered into the first group, whereas all venoms from
Loire-Atlantique, Seine-et-Marne and Haute-Savoie are found in
the second group. Eight out of 11 venoms collected in Puy-de-
Do ˆme are clustered in the first group whereas venoms from Alpes-
Maritimes and Alpes-de-Haute-Provence are distributed in
a homogeneous way in the two groups. A heterogeneity is also
noted for Vaf venoms, which are distributed into the two groups
(Figure 12). Venoms 401, 406, 458 and 514 were clearly
characterized by the over-expression of a peak at an average
molecular weight of 13753 Da. This is consistent with the
molecular weight of AtxB since we have shown that the level of
expression of AtxA is very low in the venom glands of snakes 406
and 514 [30] and only AtxB was detected in venom 406 by
microsequencing (Figure 6B).
Figure 4. Selective capture of PLA2 using SELDI ProteinChip Array. Individual venoms (2.5 mg) were applied to the surface of a WCX2 ProteinChip as
described in the Methods section. Unbound proteins and interfering substances were washed away and matrix was added and allowed to dry. The
captured proteins were detected using surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry. Normalised mass (m/z)
for each peak (in Daltons (Da)) is demonstrated on the X-axis, while intensity (mA) is plotted on the Y-axis. m/z ratios from different spectra that are
within 0.2% of each other are considered as potentially the same protein.
doi:10.1371/journal.pone.0001194.g004
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Cross-reactions to Atx antibodies were previously shown to
identify the presence of neurotoxins (Atx and/or vaspin) in the
blood of patients presenting neurological symptoms following
snake bite by vipers in ‘‘Alpes-Maritimes’’ and ‘‘Alpes-de-Haute-
Provence’’ (south-east of France) [18]. The same approach was
therefore used to identify snakes that express neurotoxins in their
venom (Table 3). Vaa venoms from Loire-Atlantique, Seine-et-
Marne and Haute-Savoie did not show any cross-reaction with
anti-Atx antibodies consistent with the absence of neurological
cases of envenomation in these areas (Table 3). Vu venom 620
(Table 3) and Vu venoms from Alpes-Maritimes (data not shown)
did not cross-react with Atx, showing that vaspin expression is low
or inexistent. Venoms from Puy-de-Do ˆme had diverse cross-
reactivities ranging from 0 to 2 depending on their area of capture.
A higher heterogeneity was observed among venoms from Alpes-
de-Haute-Provence with cross-reactivities ranging from 0 to 4.
The Atx cross-reaction scores for snake venoms from Hautes-
Pyre ´ne ´es were between 1 and 3. Venoms from He ´rault and Haute-
Garonne were all highly reactive with anti-Atx antibodies. We also
tested the cross-reactivities of Vaz venom samples collected in
other departments of the south-west of France: Tarn (code no. 81),
Aveyron (code no. 12), Pyre ´ne ´es-Atlantique (code no. 64), Aude
(code no. 11) and Pyre ´ne ´es Orientales (code no. 66). They all
presented maximum scores of cross-reactions (data not shown).
Venoms from Vll from Burgos (Spain) did not show any cross-
reactivity with anti-Atx antibodies, consistent with the PLA2
composition of the Vll genome, which includes only AmI1 and
AmI2 genes. Vaf venoms collected in Tuscany, Liguria and
Calabria (Italy) showed Atx cross-reactivity scores of 1 to 3.
Interestingly, all venoms from SELDI group 1 but one (452) had
Atx cross-reactivities ranging from 1 to 4 whereas 73% of venom
from group 2 did not cross-react with Atx. This observation shows
that the SELDI technology is definitely efficient to differentiate
Vaz-type neurotoxic venoms from classical ones. Neurotoxic
atypical venoms like those from the south-east of France are less
easily identified unless they clearly over-express Atx, which can be
easily identified in the heat map.
Figure 5. Isolation of PLA2 fractions from pooled Vaa and pooled Vaz venoms on Sephadex G100 Superfine column. (A) Pooled Vaa and (B)
pooled Vaz were fractionated on Sephadex G100 superfine as described in the Material and Methods section. Fractions containing PLA2 activity are
shown in red.
doi:10.1371/journal.pone.0001194.g005
Figure 6. PLA2 analysis by SELDI and SDS-PAGE. A) Vaa and Vaz PLA2 fractions isolated from pooled venoms as shown in Figure 5 were spotted on
WCX2 ProteinChips. Normalised mass (m/z) for each peak (in Daltons (Da)) is demonstrated on the X-axis, while intensity (mA) is plotted on the Y-axis.
B) Venoms 406 and 508 were separated by SDS-PAGE on a 20% homogeneous acrylamide gel under reducing conditions. N-terminal and internal
sequences were determined as described in the Material and Methods section.
doi:10.1371/journal.pone.0001194.g006
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venoms and cases of envenomation
The unusual features of immunological cross-reactions observed in
Puy-de-Do ˆme, Alpes-Maritimes and Alpes-de-Haute-Provence as
well as the complexity of their classification according to their
proteomic profile prompted us to compare the geographical
distribution of snake venom data and cases of envenomation. The
Vipera aspis vipers of Puy-de-Do ˆme whose venom belong to SELDI
group 1 (CiphergenExpress) and cross-react with Atx are grouped in
the south-west of the department (Figure 13). These venoms were
classified in the same group as that of Vaz venoms from Hautes-
Pyre ´ne ´es. Interestingly, only classical features of Vipera aspis
envenomations were observed for patients collected at Clermont-
Ferrand hospital. However, it must be specified that the localization
of the geographical sector where the bite took place is not specified
by the epidemiologic investigation. The distribution was more
complex in Alpes-Maritimes and Alpes-de-Haute-Provence
(Figure 14). In Alpes-Maritimes, all snakes and all envenomation
cases were neurotoxic as far as they were located at distance of the
mediterraneancoast.InAlpes-de-Haute-Provence,anequalnumber
of neurotoxic and non-neurotoxic venoms and envenomations were
reported. At Digne-les-Bains, a classical envenomation was observed
and a non-neurotoxic viper was captured. At Colmars-les-Alpes,
a neurotoxic case was reported whereas both neurotoxic and non-
neurotoxic snakes were captured.
Figure 7. SELDI profiles of venoms from Seine-et-Marne (code no. 77) and Loire-Atlantique (code no. 44). Peaks matching the molecular weights
of AmI1 and AmI2 are indicated on the spectra.
doi:10.1371/journal.pone.0001194.g007
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Cases of neurological envenomation by Vipera aspis snakes have
regularly been reported since 1992 in the south-east of France
(Alpes-Maritimes and Alpes-de-Haute-Provence). The presence of
genes encoding PLA2 neurotoxins in the Vaa snake genome led us
to conduct an epidemiological survey of snake bite in various
regions of France. Neurological signs were reported after snake
bite in three regions of France: Languedoc-Roussillon, Midi-
Pyre ´ne ´es and PACA. All cases involved ptosis, which appears as
a characteristic sign of neurotoxic Vipera aspis envenomations. The
time to between envenomation and the onset of symptoms was
variable, but symptom onset was often late. Ptosis and ophtalmo-
plegia, two of most frequent symptoms, were shown to occur after
9.0365.6 hrs and 1066.12 hrs respectively.
The clinical symptoms observed in ‘‘Alpes-Maritimes’’ and
‘‘Aveyron’’ were the most diverse, with nine different neurological
signs. The diversity of symptoms observed was not related to the
severity of envenomation, or to the age of the patients. Moreover,
similar symptoms were observed after envenomation by venoms
containing vaspin or ammodytoxin. This was true whether these
toxins acted at the presynaptic part of the neuromuscular junction,
like the momomeric ammodytoxin, or bound to the postsynaptic
part, like heterodimeric vaspin.
Figure 8. SELDI profiles of venoms from Puy-de-Do ˆme (code no. 63). Peak molecular weights consistent with those of PLA2s are indicated on the
spectra.
doi:10.1371/journal.pone.0001194.g008
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PLoS ONE | www.plosone.org 11 November 2007 | Issue 11 | e1194We used several approaches to characterize the venom PLA2
composition of snakes captured in the areas in which the
epidemiological survey was performed. We analyzed the genes and
transcripts encoding venom PLA2s. We used SELDI technology to
study the diversity of PLA2 neurotoxins in various venom samples.
Electrospray and MALDI-MS is a faster, more accurate approach
than SDS-PAGE for the characterization of venom components
[31,32]. SELDI-TOF-MS can be considered as an extension of the
matrix-assisted laser desorption/ionization (MALDI)-TOF-MS
method [33]. In the SELDI method, protein solutions are applied
tothe spotsof ProteinChipArrays, which havebeenderivatized with
planar chromatographic chemistries. The proteins actively interact
with the chromatographic array surface, and become sequestered as
well as separated from salts and other sample contaminants by
subsequent on-spot washing with appropriate buffer solutions.
Prefractionation, a sample preparation prerequisite that complicates
the MALDI analysis, often resulting in sample loss as well as
artifactual qualitative and quantitative variances, is therefore not
required for SELDI analyses. This is particularly interesting if one
works with samples of which the quantities are reduced. In parallel,
we evaluated venom neurotoxicity by analyzing cross-reactivity with
anti-Atx antibodies. We have previously used this method to detect
neurotoxins in the blood of patients bitten by vipers in the south-east
of France who presented neurological symptoms [18]. Three snake
populations were identified as worthy of particular attention based
on their neurotoxic venom PLA2 content.
Figure 9. SELDI profiles of venoms from the south-west of France. Peak molecular weights consistent with those of PLA2s are indicated on the
spectra.
doi:10.1371/journal.pone.0001194.g009
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PLoS ONE | www.plosone.org 12 November 2007 | Issue 11 | e1194The genomic analysis of snakes captured in the south-east of
France revealed considerable diversity in the genes encoding
PLA2. Genes encoding two types of neurotoxin, Atx isoforms and
vaspin, were identified. These genes were not constantly
expressed, as shown by transcriptome data. Consistent with this
finding, venom SELDI profiles and neurotoxin production were
highly variable and diverse. This finding is consistent with the
substantial variability of symptoms in this region, in which both
neurotoxic and classical envenomations are reported (Figure 14).
The genomes of Vaz snakes from Gironde and Hautes-Pyre ´ne ´es
were characterized by the absence of the AmI2 gene. Venom
PLA2 profiles were highly homogeneous. All contained neurotoxic
PLA2s, regardless of where the snakes were captured. However,
neurotoxin levels varied between venom samples, with the lowest
level of variability for snakes from the center of the range of
distribution and the highest level of variability for snakes collected
in zones of intergradation between Vaz and Vaa snakes.
The genomes of Vaa snakes from Puy-de-Do ˆme were very
similar to those of Vaa snakes from Pays-de-la-Loire, but one snake
did not possess an AmI2 gene; interestingly, vaspin transcripts
were detected in this snake only. SELDI profiles of venoms from
Puy-de-Do ˆme revealed that PLA2 composition was related to the
Figure 10. SELDI profiles of venoms from the south-east of France. Peak molecular weights consistent with those of PLA2s are indicated on the
spectra.
doi:10.1371/journal.pone.0001194.g010
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PLoS ONE | www.plosone.org 13 November 2007 | Issue 11 | e1194geographic location of the corresponding snake. Venoms from the
west of the department were identical to Vaz venoms, and
contained vaspin. Those from the center and east of the
department displayed heterogeneous profiles, and no cross-
reaction with anti-Atx antibodies was reported.
Our results raise two issues concerning the clinical expression of
venom neurotoxicity and the origin of the two neurotoxic
populations of Vaa.
A correlation was found between the expression of neurological
symptoms in humans and the intensity of the cross-reaction of
venoms with anti-Atx antibodies, which is correlated with the level
of neurotoxin expression. Neurotoxic envenomations were re-
ported only in the areas with the highest scores of Atx cross-
reactivity. Atx cross-reactivity scores of 4 are frequent for snake
venoms in the south-east of France, where neurotoxic envenoma-
tions have been regularly reported (Supplementary Table S2,
Figure 14). No such score was ever reported for snakes from Puy-
de-Do ˆme and only ‘‘classical’’ symptoms of Vaa snake envenoma-
tions were observed in this area (Supplementary Table S2,
Figure 13). This was also true in the neighboring departments to
the west: Creuse (code no. 23), and Corre `ze (code no. 19) (hospital
of Ussel, personnal communication). Atx cross-reactivity scores of
4 were mainly observed on the periphery of the distribution range
of Vaz snakes. No neurological symptoms associated with Vaz
snake bites were described in a retrospective survey of 240 Vaz
envenomations during the last 40 years in the south-west of France
[34]. Another retrospective survey performed between 1995 and
2000 confirmed the absence of neurological signs following Vaz
bites in the Aquitaine region [35]. The neurological symptoms
reported after one Vaz bite in this region were mild and not
convincing according to our criteria [36]. The patient suffered
only drowsiness and muscle weakness, with no ptosis. Thus,
neurological signs including ptosis have only been observed in
He ´rault and Aveyron (as previously described by [37]). Venoms
tested in these departments also presented the highest scores for
Atx cross-reactivity. Thus, the amount of vaspin was shown to vary
between snakes. Intergradation areas were sites of high levels of
vaspin expression. Snakes captured in Haute-Garonne and
Languedoc-Roussillon are probably hybrids between Vaa and
Vaz snakes, as suggested by the following factors: 1) difficulties in
identifying clearly their subspecies; 2) the heterogeneity of their
PLA2 SELDI profiles, which demonstrated the expression of AmI2
in the venom of two snakes; 3) the composition of their venoms
that present by SDS-PAGE bands specific of Vaa venoms as shown
in Figure 15.
We will now consider the origin of the two neurotoxic
populations of Vaa. Two data sets must be considered for the
southeastern neurotoxic snake population: 1) the regular reports of
neurotoxic envenomations in south-east France since 1992
suggesting the recent appearance of a new snake population and
2) the presence of genes encoding Atx isoform genes and Bov-B
line retroposons in the genome of this neurotoxic snake
population. We found published reports of envenomations with
neurological signs in four departments of PACA: 1) Alpes-
Maritimes [38], 2) Alpes-de-Haute-Provence [39,40], 3) Hautes-
Alpes, and 4) Vaucluse [41]. The case from Alpes-de-Haute-
Provence [40] was wrongly attributed to Vipera ursinii, which can
clearly be excluded in light of recent observations [42]. These data
indicate that the neurotoxic Vipera aspis population of the south-
east of France did not appear in the nineties. Thus, regular report
of neurotoxic snake bites in south-east France may be explained
either by the careful survey performed by the Poison Center of
Marseilles since the start of the 1990’s, which could have
highlighted neurotoxic snake bites or to the modification of the
neurotoxic snake population behaviour. Interestingly, the epide-
miological survey has indicated that most of the neurotoxic snake
Figure 11. SELDI profiles of venoms from Haute-Savoie (code no. 74) and Italy. Peak molecular weights consistent with those of PLA2s are
indicated on the spectra.
doi:10.1371/journal.pone.0001194.g011
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PLoS ONE | www.plosone.org 14 November 2007 | Issue 11 | e1194bites occurred near dwellings or inside towns. The consecutive
rarefaction of the preys to forest fires and to the drought that has
prevailed for a few years in the south-east of France could explain
this phenomenon.
We analyzed the occurrence of neurotoxic envenomations in
neighboring countries. We also analyzed the genome, transcrip-
tome and proteome characteristics of snake venoms in these
countries. Neurological cases attributed to Vaf snake bites were
reported in Italy from 1989 to 1995 [43,44]. The symptoms
described, and their timing did not significantly differ from our
observations. The genome of the Vaf captured in Piemont (Italy)
contains vaspin genes, but no Atx genes. Vaatra is present in Italy,
at the border with France. This species is also present in
Switzerland, but no case of neurotoxic envenomation associated
with Vaatra snake bite has ever been reported by the Swiss
National Poison Center of Zurich (personal communication).
These observations are consistent with our genomic analysis
indicating that the Vaatra genome contains no genes encoding
neurotoxins. We suggest that the French neurotoxic snake
population has resulted from hybridization between Vipera aspis
and Vipera ammodytes. The following observations support this view:
1) natural hybrids between Vaf and Vam rufoi can be found in the
north-east of Italy, where these two species cohabit, 2) a phyloge-
Figure 12. Heatmap obtained with clusters with p-values,0.05. Each
column in the heatmap corresponds to a spectrum, each row to
a cluster (or a potential biomarker), and each cell to a peak, with the
colour indicating intensity of expression (green: low expression, red:
high expression). Related spectra are sorted and grouped according to
similarity, resulting in the dendrogram. The length of a branch is
inversely proportional to the relatedness of the spectra. Average
normalised mass (m/z) of the 4 clusters with p-values,0.05 are
indicated on the right of the heatmap.
doi:10.1371/journal.pone.0001194.g012
Table 3. Evaluation of neurotoxicity of venoms collected in
France by measuring cross-reactivity to AtxA antibodies.
......................................................................
Label number
Administrative
department
Viper
identification
Cross-
reaction
with AtxA
402, 403, 404 Alpes-de-Haute-
Provence (04)
Vaa 0
405 Alpes-de-Haute-
Provence (04)
Va ? 0
651 Haute-Savoie (74) Vaatra 0
712, 713,714,
715, 716
Haute-Savoie (74) Vaa 0
564, 602 He ´rault (34) Vaa
«garrigue»
0
301, 303, 304, 312 Loire-Atlantique (44) Vaa 0
452, 453, 454, 455, 501,
502, 503, 551, 601, 561
Puy-de-Do ˆme (63) Vaa 0
778, 779, 783, 784 Seine-et-Marne (77) Vaa 0
620 Vaucluse (84) Vu 0
800 Alpes-Maritimes (06) Vaa 1
508, 519 Hautes-Pyre ´ne ´es (65) Vaz 1
552, 559 Puy-de-Do ˆme (63) Vaa 1
510, 512, 521, 553, 554 Puy-de-Do ˆme (63) Va ? 1
513 Alpes-de-Haute-
Provence (04)
Va ? 2
613 Gironde (33) Vaz 2
516, 528 Hautes-Pyre ´ne ´es (65) Vaz 2
451 Puy-de-Do ˆme (63) Va? 2
456, 560 Puy-de-Do ˆme (63) Vaa 2
527 Hautes-Pyre ´ne ´es (65) Vaz 3
401, 406, 458 Alpes-de-Haute-
Provence (04)
Vaa 4
514 Alpes-de-Haute-
Provence (04)
Va? 4
603 Alpes-Maritimes (06) Vaa 4
565 Gironde (33) Vaz 4
459 Haute-Garonne (31) Vaz 4
504, 505, 506, 509 He ´rault (34) Va? 4
Cross-reactions to AtxA antibodies were tested by ELISA as described in the
Material and Methods section. Optical densities measured at dilutions of anti-
AtxA IgG of 1/16,000 were used for cross-reactivity gradation: level 0: OD#0.1,
level 1: 0.1,OD#0.2; level 2: 0.2,OD#0.3; level 3: 0.3,OD#0.4; level 4:
OD.0.4.
doi:10.1371/journal.pone.0001194.t003
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PLoS ONE | www.plosone.org 15 November 2007 | Issue 11 | e1194Figure 13. Snake venom characteristics and type of grade 2 and 3 envenomations observed in Puy-de-Do ˆme (code no. 63). Envenomation cases
are presented in circles and snake venoms in rectangles. Classical venoms or envenomations cases are in white and neurotoxic venoms and
envenomations are reported in black.
doi:10.1371/journal.pone.0001194.g013
Figure 14. Snake venom characteristics and type of grade 2 and 3 envenomations observed in Alpes-de-Haute-Provence (code no. 04) and
Alpes-Maritimes (code no. 06). Envenomation cases are presented in circles and snake venoms in rectangles. Classical venoms or envenomations
cases are in white and neurotoxic venoms and envenomations are reported in black. The white line indicates the border between the two
deparments.
doi:10.1371/journal.pone.0001194.g014
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PLoS ONE | www.plosone.org 16 November 2007 | Issue 11 | e1194netic analysis of V. aspis snakes has shown that ‘‘neurotoxic’’ Vaa
collected in south-eastern France belong to a phylogenetic group
separate from that containing the other French specimens of this
subspecies [27]. According to epidemiological data, the neurotoxic
snake population spans the territory of at least four departments.
Given the low dispersion rate of these snakes, the hybridization
event was probably not recent and may have occurred in refuge
areas during the last period of glaciation. The Southern Alps (Italy)
served as refuge areas for V. aspis and V. ammodytes snakes during
several ice ages [45,46]. Moreover, analysis of the phylogeography
of V. aspis has suggested the existence of refuge areas in south-
eastern France [47]. This is consistent with the presence of Atx
genes and Bov-b line retroposons in the genomes of Vaf captured
in the south of Italy, and of Vammon from Bulgaria.
The origin of the neurotoxic population of Puy-de-Do ˆme
appears different. All neurotoxic individuals are clustered in the
south-west part of the department, near the tributaries of the
Dordogne River, which flow into the Gironde. These snakes may
have originated from the Vaz population of Gironde. They may
have colonized northern areas from the ice refuges of the south-
west of France, by moving along the rivers, which constitute
thermal corridors. Their PLA2 profile is consistent with this
possibility, because their genomes, like those of Vaz snakes, contain
no AmI2 gene. Our analysis of PLA2 SELDI profiles suggests that
the area of distribution of this potentially neurotoxic snake
population to the east may be limited towards the west by the
Massif Central Mountains. More studies must be performed on
snake venoms from the east part of the department to define the
range of this neurotoxic population.
Fry et al. recently reconsidered the very concept of ‘‘non-
venomous’’ snakes after studying the transcriptomes of the venom
gland of non-front-fanged snakes: these transcriptomes contain
sequences encoding several toxin types [48,49]. Similarly, our
study shows that we have to reconsider Vipera aspis aspis as
a ‘‘cryptoneurotoxic’’ species. Its genome contains an arsenal of
PLA2 neurotoxins ready to be expressed under stimuli that still
need to be identified. Our work demonstrates that a multidisci-
plinary approach can fully characterize the diversity in snake
venom composition and identify its medical and public health
consequences. Thus, by combining epidemiological data concern-
ing snake bites with genomic, tanscriptomic, proteomic and
immunochemical analyses of the major toxic components of
venoms, we were able to provide a clear description of the
potential neurotoxicity of Vipera aspis bites in France. These
observations as a whole illustrate the biodiversity of venoms of the
genus Vipera. The geographical variations in the composition of
Vipera aspis venom have major consequences for the preparation of
neutralizing antivenoms [50,51]. Indeed, it strengthens the
arguments in support of the use of polyvalent antivenoms able
to neutralize the venom of Vipera aspis, Vipera berus and Vipera
ammodytes in the treatment of viper envenomations in France.
SUPPORTING INFORMATION
Table S1
Found at: doi:10.1371/journal.pone.0001194.s001 (0.17 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001194.s002 (0.24 MB
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Figure 15. Hybrid SDS-PAGE venom profiles from snakes captured in He ´rault (code no. 34) and Haute-Garonne (code no. 31). Venoms 504, 505,
and 509 from He ´rault, 459 from Haute-Garonne, Vaz-type venoms 508, 516, 519, 527, 528 from Hautes-Pyre ´ne ´es and Vaa-type venom 303 from Loire-
Atlantique were separated by a 20% SDS-PAGE under denaturating and reducing condtitions. Molecular weight markers are shown on the left.
Arrows indicate protein bands specifically found in Vaa venoms.
doi:10.1371/journal.pone.0001194.g015
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